• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

KalVista Pharmaceuticals (KALV)

Common Shares
Sell: $11.10|Buy: $12.00|Change: 0.06 (0.54%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Find out more

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Address

55 Cambridge Parkway
Suite 901 East
Cambridge
MA
USA
02142

Telephone

+1 857 9990808

Website

https://www.kalvista.com

Sector 

Healthcare

Forecast key dates

NameKey Date
KalVista Pharmaceuticals Inc Annual General Meeting for 20262026-10-01T13:00:00
KalVista Pharmaceuticals Inc First Quarter Earnings Conference Call for 20272026-09-11T08:30:00
KalVista Pharmaceuticals Inc First Quarter Earnings Results for 20272026-09-11T00:00:00
KalVista Pharmaceuticals Inc Annual Report for 20262026-07-10T00:00:00
KalVista Pharmaceuticals Inc Fourth Quarter Earnings Results for 20262026-07-07T00:00:00
KalVista Pharmaceuticals Inc Third Quarter Earnings Results for 20262026-03-12T00:00:00
KalVista Pharmaceuticals Inc Second Quarter Earnings Results for 20262025-12-05T00:00:00
KalVista Pharmaceuticals Inc Annual General Meeting for 20252025-10-01T13:00:00

Previous key dates

NameKey Date
KalVista Pharmaceuticals Inc Annual General Meeting for 20252025-10-01T13:00:00
KalVista Pharmaceuticals Inc First Quarter Earnings Conference Call for 20262025-09-11T08:30:00
KalVista Pharmaceuticals Inc First Quarter Earnings Results for 20262025-09-11T00:00:00
Cantor Global Healthcare Conference 20252025-09-03T10:55:00
KalVista Pharmaceuticals Inc Annual Report for 20252025-07-10T00:00:00
KalVista Pharmaceuticals Inc Fourth Quarter Earnings Results for 20252025-07-07T00:00:00
Jefferies Global Healthcare Conference2025-06-05T08:45:00
The Citizens Life Sciences Conference2025-05-07T11:30:00
24th Annual Needham Virtual Healthcare Conference2025-04-07T13:30:00
KalVista Investor Event2025-03-25T08:00:00
KalVista Pharmaceuticals Inc Third Quarter Earnings Results for 20252025-03-12T00:00:00
Leerink's Global Healthcare Conference 20252025-03-10T08:00:00
TD Cowen 45th Annual Health Care Conference2025-03-04T13:10:00
KalVista Pharmaceuticals Inc Second Quarter Earnings Results for 20252024-12-05T00:00:00
Jefferies London Healthcare Conference2024-11-21T11:00:00
Stifel 2024 Healthcare Conference2024-11-19T09:10:00
KalVista Pharmaceuticals Inc Annual General Meeting for 20242024-10-03T09:30:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.